Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A macrolide antibiotic that is approved for pediatric use. Frequently used in young infants
At latest update no published data on excretion into breast milk were found.
It has higher molecular weight and shorter half-life elimination span than other macrolide antibiotics like azithromycin and claritormycin that are excreted into breast milk in negligible amount.
Until more published information about this drug regarding breastfeeding appears, it may be preferable a known and safer alternative, especially during the neonatal period and in cases of prematurity.
Early exposure to macrolide antibiotics (especially erythromycin) has been linked to hypertrophic pyloric stenosis, even through breast milk, being it a reason to avoid them during the first month of breastfeeding.
Take into account the possible negative results of bacterial cultures among febrile infants when their mothers are on antibiotics, as well as the possibility of gastroenteritis by altering the intestinal flora.